Infections of cefotaxime-resistant and cefmetazole-susceptible Escherichia coli and Klebsiella pneumoniae in children.

A search of the computerized database at the National Taiwan University Hospital was made for cefotaxime-resistant and cefmetazole-susceptible isolates of Escherichia coli and Klebsiella pneumoniae (which may be extended-spectrum beta-lactamase-producing strains) in pediatric wards and intensive care units between 1999 and 2001. Fourteen infectious episodes attributed only to study bacteria were identified, including 7 episodes of bacteremia. Nine patients (64.3%) had underlying medical conditions: 3 were premature babies, 3 were immunodeficient, 2 had malignancy, and 2 had a congenital heart disease with active heart failure even after surgery. Among the 7 patients with bacteremias, 5 may be catheter-related; 6 were treated with carbapenems and 1 was treated with cefmetazole successfully, with or without the removal of the catheter. Before the acquisition of the infection, a history of stay in an intensive care unit within 4 weeks was noted in 10 cases (71.4%); a history of use of extended-spectrum cephalosporins within 4 weeks was also noted in 6 cases (42.9%). Cefmetazole, with or without an aminoglycoside, was clinically effective in 6 cases (42.8%). Except for 1 episode of pneumonia that ended in mortality, all of the infectious episodes were successfully treated. The mortality rate was 7.1%.

[1]  D. Maki,et al.  The Commonality of Risk Factors for Nosocomial Colonization and Infection with Antimicrobial-Resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida , 2002, Annals of Internal Medicine.

[2]  S. H. Jeong,et al.  Antibiotic susceptibility of bacterial strains isolated from patients with various infections , 2002, Letters in applied microbiology.

[3]  P. Hsueh,et al.  Antimicrobial Drug Resistance in Pathogens Causing Nosocomial Infections at a University Hospital in Taiwan, 1981-1999 , 2002, Emerging infectious diseases.

[4]  Y. Ishii,et al.  Properties of extended-spectrum β-lactamases constructed by site-directed mutagenesis , 2002, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  H. Nikaido Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. , 2001, Seminars in cell & developmental biology.

[6]  Victor L. Yu,et al.  Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory , 2001, Journal of Clinical Microbiology.

[7]  J. Patterson,et al.  Antibiotic utilization: is there an effect on antimicrobial resistance? , 2001, Chest.

[8]  J. Wu,et al.  Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. , 2001, Microbial drug resistance.

[9]  J. Pagés,et al.  Membrane permeability modifications are involved in antibiotic resistance in Klebsiella pneumoniae. , 2000, Biochemical and biophysical research communications.

[10]  J. Steckelberg,et al.  Clinical aspects of antimicrobial resistance. , 2000, Mayo Clinic proceedings.

[11]  Chin‐Yun Lee,et al.  Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli andKlebsiella pneumoniae in a Pediatric Oncology Ward: Clinical Features and Identification of Different Plasmids Carrying both SHV-5 and TEM-1 Genes , 1999, Journal of Clinical Microbiology.

[12]  K. Choe,et al.  Survey of Extended-Spectrum β-Lactamases in Clinical Isolates of Escherichia coli and Klebsiella pneumoniae: Prevalence of TEM-52 in Korea , 1999, Journal of Clinical Microbiology.

[13]  L. Martínez-Martínez,et al.  Outer Membrane Profiles of Clonally Related Klebsiella pneumoniae Isolates from Clinical Samples and Activities of Cephalosporins and Carbapenems , 1998, Antimicrobial Agents and Chemotherapy.

[14]  J. Pitout,et al.  Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. , 1997, The American journal of medicine.

[15]  A. Medeiros,et al.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Moellering,et al.  Antimicrobial-drug resistance. , 1996, The New England journal of medicine.

[17]  R A Weinstein,et al.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. , 1996, The Journal of infectious diseases.

[18]  A. Sturm,et al.  Treatment failure due to extended spectrum beta-lactamase. , 1996, The Journal of antimicrobial chemotherapy.

[19]  K. Kaye,et al.  Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. , 2004, Infectious disease clinics of North America.

[20]  S. Amyes,et al.  TEM- and SHV-derived extended-spectrum beta-lactamases: relationship between selection, structure and function. , 1995, The Journal of antimicrobial chemotherapy.

[21]  K S Meyer,et al.  Nosocomial Outbreak of Klebsiella Infection Resistant to Late-Generation Cephalosporins , 1993, Annals of Internal Medicine.

[22]  C. Bizet,et al.  In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. , 1989, The Journal of infectious diseases.

[23]  V. Jarlier,et al.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. , 1988, Reviews of infectious diseases.